The results from the six-month collaborative project have been published by Thermo Fisher in a White Paper.
The White Paper concludes that by combining Horizon’s RNA reference standards with Thermo Fisher’s Ampliseq and Oncomine fusion assays in oncology research, end-users will be provided with a robust and reliable solution compared to existing reference standards. The RNA reference standards endorsed in the White Paper, include Horizon’s additional new RNA reference standard, 5-Fusion Multiplex, which will be launched in July 2017.
Dr. Darrin M Disley, Chief Executive Officer, Horizon Discovery Group, commented: “This White Paper by Thermo Fisher reaffirms Horizon’s global leadership position in the provision of high-quality molecular reference standards. Accurate diagnostic testing is a critical component of effective patient treatment and a key contributor to minimising positive and negative errors in diagnostic results. Horizon is the pioneer and “go to” company in this important field that provides more accurate outcomes for researchers, pathology labs and, ultimately, healthcare providers and patients.”
About HDxTM Reference Standards
There are many potential sources of variability that can lead to molecular diagnostic tests providing erroneous results. HDx Reference Standards offer a source of genetically defined, quantitative, sustainable and independent third party reference material, critical to the validation and routine performance monitoring of assays, providing an unprecedented level of control. Horizon reference standards are available in broad range of formats including Formalin-Fixed Paraffin-Embedded (FFPE) cell line sections and purified genomic DNA (gDNA).
Glossary
- Assay – an analysis performed to determine the presence of a substance and the amount of that substance
- Reference standard – a highly characterized, standardised and validated material that enables the measurement of the sensitivity, specificity and accuracy of assays and workflows.
*******
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Darrin Disley, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Chris Claxton, VP Investor Relations
Tel: +44 (0) 1223 655 580
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com
_____________________________________________________